Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab vs Thymoglobulin Induction in Lung Transplantation
NCT00181142Phase 3Completed
- Sponsor
- Johns Hopkins University
- Start
- Oct 1999
- Primary completion
- Dec 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of daclizumab in lung transplant rejection (2 arms), sponsored by Johns Hopkins University. Primary endpoint: All cause mortality at 2 years. Started Oct 1999; status: completed.
02
Drugs
daclizumab
03
Conditions
lung transplant rejection
Beyond the preview
Go deeper on NCT00181142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00181142.